• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

16 January 2023

Fabio Macchi is our new Head of Medical and Quality Departments.


0 Comments1 Minute

30 March 2022

Carvykti (ciltacabtagene autoleucel), new gene therapy to treat adult patients with multiple myeloma


0 Comments3 Minutes

11 March 2022

Jardiance (empagliflozin)approved for Wider Range of Patients with Heart Failure


0 Comments3 Minutes

9 March 2022

Kimmtrak (tebentafusp), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer.


0 Comments3 Minutes

7 February 2022

Breyanzi (lisocabtagene maraleucel) New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma


0 Comments4 Minutes

3 November 2021

Cyltezo(adalimumab-adbm), the First Interchangeable Biosimilar to Humira


0 Comments3 Minutes

25 October 2021

Trodelvy (sacituzumab govitecan), First-in-class medicine to treat aggressive form of breast cancer


0 Comments3 Minutes

21 September 2021

Byooviz (ranibizumab-nuna), First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions


0 Comments3 Minutes

18 June 2021

Astepro (azelastine hydrochloride nasal spray, 0.15%), nasal antihistamine approved for nonprescription use


0 Comments2 Minutes

8 June 2021

Aduhelm (aducanumab), first new Alzheimer’s drug in 20 years.


0 Comments5 Minutes

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com